Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations

Pristauz G, Petru E, Stacher E, Geigl J B, Schwarzbraun T, Tsybrovskyy O, Winter R & Moinfar F
(2010) Histopathology57, 877–884

[1]  E. Robecchi.  [Pathology of the breast]. , 1954, Minerva ginecologica.

[2]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[3]  F. Berrino,et al.  Serum and urinary androgens and risk of breast cancer in postmenopausal women. , 1991, Cancer research.

[4]  G. Secreto,et al.  Abnormal production of androgens in women with breast cancer. , 1994, Anticancer research.

[5]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[6]  T. H. van der Kwast,et al.  The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. , 1996, European journal of cancer.

[7]  D. Horsfall,et al.  Expression of the androgen receptor and an androgen-responsive protein, apolipoprotein D, in human breast cancer. , 1996, British Journal of Cancer.

[8]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[9]  M B Daly,et al.  Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. , 1999, American journal of human genetics.

[10]  M. Erdos,et al.  BRCA1 inhibition of estrogen receptor signaling in transfected cells. , 1999, Science.

[11]  D. Livingston,et al.  In search of the tumour-suppressor functions of BRCA1 and BRCA2 , 2000, Nature.

[12]  R A Irvine,et al.  Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. , 2000, Cancer research.

[13]  I. Fentiman,et al.  Urinary androgens and breast cancer risk: results from a long-term prospective study based in Guernsey , 2000, British Journal of Cancer.

[14]  F. Rousseau,et al.  Short polyglutamine tracts in the androgen receptor are protective against breast cancer in the general population. , 2001, Cancer research.

[15]  M. King,et al.  BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. , 2001, Human molecular genetics.

[16]  A. Meindl,et al.  Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population , 2002, International journal of cancer.

[17]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[18]  R. Wooster,et al.  Breast and ovarian cancer. , 2003, The New England journal of medicine.

[19]  H. Denk,et al.  Androgen receptors frequently are expressed in breast carcinomas , 2003, Cancer.

[20]  T. H. van der Kwast,et al.  Androgen Pathway Dysregulation in BRCA1-Mutated Breast Tumors , 2003, Breast Cancer Research and Treatment.

[21]  John B. Adams.  Adrenal androgens and human breast cancer: A new appraisal , 1998, Breast Cancer Research and Treatment.

[22]  R. Shore,et al.  Postmenopausal levels of sex hormones and risk of breast carcinoma in situ: Results of a prospective study , 2005, International journal of cancer.

[23]  N. Harada,et al.  Estrogen-metabolizing enzymes in breast cancers from women over the age of 80 years. , 2006, The Journal of clinical endocrinology and metabolism.

[24]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[25]  A. Musolino,et al.  BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study. , 2007, Breast.

[26]  Z. Shao,et al.  The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified , 2008, Breast Cancer Research and Treatment.

[27]  Dieter Niederacher,et al.  MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early‐onset cases , 2008, Human mutation.

[28]  R. Gelber,et al.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  G. Viale,et al.  Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers , 2010, Breast Cancer Research and Treatment.